2014-03-14 08:42:03 - ROCHE, Confidence Building up on Next Gen. Rituxan (GA101) - a new market research report on companiesandmarkets.com
Roche seems to be on track of delivering sustainable growth as it announced today that Obinutuzumab (GA-101), follow-on biologic to Rituxan has demonstrated significant improvement of PFS against chemotherapy in first-line CLL in the first PhIII study. The DSMB has given a green signal to continue the study as futility analysis comparing GA-101 plus chlorambucil against Rituxan plus chlorambucil indicates potential superiority of GA-101 over Rituxan.
Superiority claim over Rituxan will allow the company to protect its revenue from any biosimilar threat going forward. With Perjeta and T-DM1 as well shaping up well, Roche is on a strong ground to sustain its revenues from Herceptin and Rituxan (~12 billion). Biosimilar Rituxan is expected to reach the market in 2016, but by
then, Roche would have GA101 on the market which would fend off any potential impact on revenues.
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.